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The human retina is a complex, multi-layered structure
of neuroectoderm-derived cells that are highly differentiated
to perform specific tasks in the detection of light and its inte-
gration and processing into visual signals. The specialized
functions of these cells together with the various cell types
providing their metabolic and structural support is dependent
on the activity of a sophisticated network of retinally expressed
genes. In an ongoing project, we are aiming to identify, char-
acterize, and catalog the genes that are expressed exclusively
or predominantly in the retinal tissue.
The retina is affected by a host of hereditary retinopa-
thies, the underlying genes for many of which have not yet
been identified (RetNet). A comprehensive gene catalog can
be used as a source for candidate genes, selected by their chro-
mosomal locations and potential functional properties. These
genes can also be systematically evaluated as potential pre-
disposing factors for complex retinopathies such as age-re-
lated macular degeneration (AMD). AMD is an incurable cause
of visual impairment that is expected to affect more than 16
million people worldwide by the year 2030 [1]. Ultimately, a
full characterization of the retinal transcriptome will serve as
a valuable reference for basic research into retinal physiol-
ogy, facilitating the study of proteins that are integral to reti-
nal structure and function.
Our approach involves the expression profiling of retina
ESTs retrieved from the UniGene Human Sequences Collec-
tion [2]. Its application has led to the identification of several
retinal genes encoding for example a G protein-coupled re-
ceptor [3] or a novel member of the MAGUK protein family
[4]. Here, we report the further characterization of a transcript,
identified as a retina-specific EST cluster, Hs. 60473, which,
by RT-PCR and Northern blot analysis, appears to be uniquely
transcribed in the human retina. The gene maps to the same
region of chromosome 7p as the gene for dominant cystoid
macular dystrophy (CYMD). CYMD is an autosomal domi-
nantly inherited condition causing the early onset of a cystic
edema in the posterior pole of the eye [5]. We have performed
comprehensive mutation analysis in CYMD patients and dem-
onstrate that this gene is not responsible for the retinal pheno-
type in these individuals.
METHODS
Isolation of the full-length cDNA and assignment of chromo-
somal location:  EST cluster Hs.60473 was retrieved from the
UniGene Human Sequences Collection (release number 113,
June 2000). A retina cDNA library constructed in the TriplEx2
© 2002 Molecular Vision
Genomic structure and assessment of the retinally expressed
RFamide-related peptide gene in dominant cystoid macular
dystrophy
Heidi L. Schulz,1 Heidi Stoehr,1 Karen White,1 Marc A. van Driel,2 Carel B. Hoyng,3 Frans Cremers,2 Bernhard
H. F. Weber1
1Institut für Humangenetik, Universität Würzburg, D-97074 Würzburg, Germany; Departments of 2Human Genetics and 3Ophthal-
mology, University Medical Center Nijmegen, 6500 Nijmegen HB, The Netherlands
Purpose: Computer-assisted sampling of EST data contained within the UniGene human sequences collection is being
used to establish a catalog of novel genes that are expressed exclusively or predominantly in the human retina. This
provides a valuable source for candidate genes possibly involved in retinal degeneration. In this report we present the
characterization of the C7orf9 gene locus encoding RFamide-related peptides (RFRPs) and its evaluation in dominant
cystoid macular dystrophy (CYMD).
Methods: Bioinformatics and cDNA library screening were used to isolate the full-length cDNA sequence and to deter-
mine the genomic organization of C7orf9. Expression profiling was done by RT-PCR and Northern blot analysis. C7orf9
was evaluated as a candidate gene for CYMD by DNA sequencing and Southern blot analysis in two affected individuals
from an extended Dutch CYMD family.
Results: The C7orf9 cDNA transcript consists of 1190 bp and is organized into 3 exons on the short arm of chromosome
7 within the critical region for CYMD. The transcript is specifically expressed in the retina but not in a large range of other
human tissues. No disease-causing mutations or larger gene rearrangements were found.
Conclusions: We provide the genomic organization of the RFamide-related peptide gene, C7orf9, which encodes a pre-
cursor protein for at least two small neuropeptides, referred to as NPSF (alias RFRP-1) and NPVF (alias RFRP-3) and
show that it is abundantly expressed in the human retina. Results of our comprehensive mutation analysis suggests that
C7orf9 is not the CYMD gene.
Correspondence to: Bernhard H. F. Weber, Institut für Humangenetik,
Biozentrum, Am-Hubland, D-97074 Würzburg, Germany; Phone:
(49)931-888-4062; FAX: (49)931-888-4069; email:
bweb@biozentrum.uni-wuerzburg.de
67
vector was screened using an α32P-dCTP-labeled 199 bp DNA
fragment obtained by PCR of genomic DNA with primers
A129F (5'-TCT GAG CCT AGA GGA TAC C-3') and A129R
(5'-GAT CTC AGA GGC AGG TTG-3') designed from 5' EST
sequences of cluster Hs.60473. Filters were hybridized over-
night in 0.5 mM sodium phosphate buffer, pH 7.2, 7% SDS, 1
mM EDTA at 58 °C and washed for 20 min. in 2X SSPE/0.1%
SDS, 1X SSPE/0.1% SDS and 0.5X SSPE/0.1% SDS at 58
°C. Plasmid DNA was isolated and sequenced with primer
walking technology using an ABI 310 automated sequencer
and the ABI PRISM Ready Reaction Sequencing Kit (Perkin
Elmer, Norwalk, USA).
To extend the transcript to the initiation site, 5'-RACE
was applied to total human retina RNA according to the
supplier’s instructions (Life Technologies, Rockville, USA).
First strand cDNA synthesis was performed using the gene-
specific oligonucleotide primer A129R. A first round of PCR
was performed with the gene-specific reverse primer A129R5
(5'-TGC TGT GAA GAT TGG AGA TC-3') followed by a
nested PCR reaction with primer A129R4 (5'-AGC TTG AAG
TGG CTA AAG TC-3'). The PCR products were directly se-
quenced as desribed above.
The chromosomal location of C7orf9 was determined by
PCR-based screening of the NIGMS Human/Rodent Somatic
Cell Hybrid Panel No. 2 (Coriell Cell Repositories, Camden,
USA). Primer pair A129E1F (5'-ACA TTG GGC TGC ACA
TAG-3') and A129E1R (5'-ATG CTA CTC ACA TTA GAG
AGA TT-3') were used on the panel and amplified a 216 bp
product.
Expression studies:  RT-PCR analysis was performed as
described previously [6] using gene specific primers A129F3
(5'-TGA TCT CCA ATC TTC ACA GC-3') and A129R ampli-
fying a 244 bp cDNA fragment. For reverse transcription, com-
mercially available total RNAs from brain, fetal brain, spinal
cord, bone marrow, retina, kidney, liver, fetal liver, lung, tra-
chea, spleen, thymus, colon, skeleton muscle, prostate, testis,
uterus, placenta, adrenal gland, and salivary gland were used
(Clontech, Heidelberg, Germany). To test for RNA integrity,
primers G3PDH-ex8F (5'-ACC ACA GTC CAT GCC ATC
AC-3') and G3PDH-ex9R (5'-TCC ACC ACC CTG TTG CTG
TA-3') were used to amplify 452 bp of the ubiquitous gene
glyceraldehyde 3-phosphate dehydrogenase. For Northern blot
analysis, the 244 bp cDNA fragment was labeled with α32P-
dCTP (3000 Ci/mmol) and hybridized to a Northern blot mem-
brane containing 10 µg total RNA isolated from retina, heart,
liver and cerebellum with the RNA-Clean kit (Angewandte
Gentechnologie Systeme GmbH, Heidelberg, Germany). Hy-
bridizations were carried out overnight in 0.5 mM sodium
phosphate buffer, pH 7.2, 7% SDS, 1 mM EDTA at 65 °C.
Washings were performed for 20 min. each in 2X SSPE/0.1%
SDS, 1X SSPE/0.1% SDS and 0.5X SSPE/0.1% SDS at 65
°C. Autoradiography was done for 4 days.
Mutation analysis:  Genomic DNA was obtained from
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Figure 1. cDNA cloning and genomic structure of C7orf9.  A: A con-
sensus cDNA sequence was assembled from I.M.A.G.E. retina clones
ze34f06 and ze37g05 and cDNA clones retrieved from cDNA library
screenings. The dotted line indicates unknown sequence. B: C7orf9
comprises three coding exons which are represented by shaded boxes.
The exon and intron sizes are derived from alignment of the cDNA
to the corresponding human draft sequence. Light gray boxes repre-
sent the 5'-and 3'-untranslated regions (UTRs). Three potential
poly(A)adenylation sites are depicted as vertical black bars in the 3'-
UTR. The name and relative positions of oligonucleotide primers
utilized in the study are shown.
Figure 2. Full-length cDNA and hypothetical peptide sequence of
C7orf9.  A putative 26 amino acid signal peptide is highlighted in
gray. The two characteristic motifs for RFamide peptides are depicted
in dark gray. Three putative polyadenylation signals, AATAAA, are
underlined.
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two affected members (numbers 4716 and 10084) of a large
Dutch CYMD family previously described by Pinckers et al.
[7]. To analyse the coding region of C7orf9, the three exons
were PCR-amplified using the following oligonucleotide prim-
ers: exon 1, A129E1F and A129E1R; exon 2, 129E2F (5'-TTA
AGT TAA TTG GGG GTT TA-3') and 129E2R (5'-TAT AAC
TGC CCA TGC ACT T-3'); exon 3, A129E3F (5'-GTT GTT
CTG ATG GGT GAC-3') and A129R6 (5'-AAA TTG CCG
TTG ATG ATC C-3'). The resulting PCR products were di-
rectly sequenced as described above.
For Southern blot analysis, 10 µg of DNA each was di-
gested with restriction enzymes EcoRI, HincII, and PstI and
electrophoretically fractionated on a 0.6% agarose-TBE gel.
DNA was transferred to a HybondN+ membrane (Amersham
Pharmacia Biotech, Freiburg, Germany) and hybridized over-
night with a labeled probe obtained by amplification of retina
cDNA with A129E1F and A129E3R (5'-TTT TCT TTT CTC
CCT AAA GTC-3').
Assessment of the allele frequency of three single nucle-
otide polymorphisms:  Single-stranded conformational poly-
morphism analysis (SSCP) with primer pair A129E1F/
A129E1R was performed to establish the allele frequency of
143G->C in 46 control subjects. The allele frequency of the
alteration 172A->G was determined in 22 unaffected controls
by direct DNA sequencing. The 431C->T alteration was ana-
lyzed by MnlI restriction enzyme analysis of a 297 bp PCR
fragment amplified from genomic DNA of 79 unrelated con-
trols using primers A129F7 (5'-GTT ATT AAG ATG AGT ACA
CCT GCA GTC AAT A-3') and A129R7 (5'-GTG CTG GCA
GGT CAT GGA G-3'). All controls were of Caucasian ances-
try.
Computational analysis:  Nucleotide and protein BLAST
programs at NCBI were used for sequence homology searches
in public databases. Pattern and profile searches were per-
formed with the Simple Modular Architecture Research Tool
(SMART) at EMBL and the SignalP program.
RESULTS & DISCUSSION
Identification of the human RFamide-related peptide cDNA
C7orf9:  EST cluster Hs.60473 contains the non-overlapping
5' and 3' end sequences of two cDNA clones (ze34f06 and
ze37g05) isolated from the Soares N2b4HR retina library (Fig-
ure 1A). Fourteen additional cDNA clones with inserts rang-
ing from 0.5 to 1.2 kb were identified by screening a retina
(TriplEx2 cDNA library; Figure 1A). Sequence assembly
yielded a 1190 bp transcript, termed C7orf9 (GenBank acces-
sion number AF440392), with an open reading frame (ORF)
of 591 bp and a potential start codon (ATG) located 48 bp
downstream of the 5' end of the cDNA (Figure 2). Repeated
applications of 5'-RACE and sequencing of the resulting cDNA
fragments failed to reveal further upstream sequences suggest-
ing a comprehensive coverage of the most 5' region of the
transcript. Three putative polyadenylation signals were iden-
tified at positions 848 bp, 955 bp, and 1156 bp (Figure 2). The
ORF of C7orf9 encodes a putative 196 amino acid peptide
containing a 26 amino acid signal peptide and two LPLRFGR
motifs characteristic of a large family of secreted neuropep-
tides (Figure 2) [8,9].
BLASTN searches with the full-length cDNA sequence
revealed significant identity to two independently isolated hu-
man cDNA transcripts (GenBank accession numbers
AB040290 and AF330057). These genes have previously been
reported to encode a precursor protein for two [10] or possi-
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Figure 3. Expression analysis of C7orf9.  A: RT-PCR analysis of
C7orf9 was done using RNA from 20 different tissues. Primer pair
A129F3 and A129R amplified a 244 bp product from only retina, as
seen on the ethidium bromide-stained agarose gel. As a positive con-
trol, primers G3PDH-ex8F/G3PDH-ex9R amplified a 452 bp prod-
uct from the ubiquitous gene glyceraldehyde-3-phosphate dehydro-
genase from all tissues. B: RNA from different tissues was separated
on a formaldehyde agarose gel and stained with ethidium bromide
(left). The resulting Northern blot was probed with an α32P-dCTP-
labeled PCR product amplified by A129F3 and A129R. Two signals
at approximately 1.2 kb and 0.85 kb were detected in retina, but not
in the other tissues tested.
TABLE 1. SINGLE NUCLEOTIDE POLYMORPHISM FREQUENCY OF THREE
VARIANTS OBSERVED IN THE C7ORF9 GENE SEQUENCE
NUCLEOTIDE
EXCHANGE*      LOCATION     AMINO ACID CHANGE       ALLELE FREQUENCY
----------  --------   -----------------  ---------------
143G->C      EXON 1     M32I                G: 0.93 (N=92)
172A->G      EXON 1     D42G                A: 0.73 (N=22)
431C->T      EXON 2     P128P               C: 0.73 (N=158)
_____
*NUMBERING STARTS AT THE FIRST BASE OF THE CDNA
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bly three [11] RFamide-related peptides (RFRPs), referred to
as NPSF, NPVF and RFRP-1 to -3, respectively. In a wide
range of species, the RFRPs constitute a large family of neu-
ropeptides and are known to exert a variety of functions such
as neurotransmission, neuromodulation, cardioexcitation or
control of muscle contraction [12-14]. Hinuma et al. [11] dem-
onstrated that synthetic RFRP-1 and RFRP-3 are specific ago-
nists of an orphan G protein-coupled receptor OT7T022 pos-
sibly mediating regulatory functions in prolactin secretion.
Furthermore, endogenous RFRP-1 was purified from bovine
hypothalamus and found to consist of 35 amino acid residues
suggesting that the mature neuropeptide is generated by cleav-
age of the RFRP preprotein between residues Arg56 and Ser57
corresponding to residues Arg55 and Ser56 in human [15]
(Figure 2). The existence of endogenous RFRP-2 and RFRP-
3 remains to be shown.
Genomic structure and chromosomal localization of
C7orf9:  To determine the genomic structure of C7orf9, the
cDNA sequence was aligned to the working draft sequence of
BAC clone CTB-136N17 (GenBank accession number
AC004129). This clone contains the entire cDNA sequence
revealing three exons (GenBank accession numbers
AF440393, AF440394, and AF440395) separated by two in-
tervening sequences of 1275 bp and 1452 bp (Figure 1B). All
identified donor and acceptor splice site sequences conform
to the GT-AG rule [16]. The three exons of the gene span ap-
proximately 4 kb of genomic DNA.
The chromosomal locus of C7orf9 was assigned by PCR-
based screening of a monochromosomal human/rodent somatic
cell hybrid DNA panel to human chromosome 7 (data not
shown). Furthermore, BAC clone CTB-136N17 as well as
overlapping PAC clone RP11-1151M13 (GenBank accession
number AC083852) have previously been mapped to the short
arm of chromosome 7 refining the genomic locus of C7orf9
to 7p15-p21. In addition, alignment of C7orf9 cDNA to ge-
nomic contig NT_007902 demonstrates that the C7orf9 locus
maps approximately 64 kb proximal to cytochrom c (HCS)
and 207 kb proximal to oxysterol binding protein-like 3
(OSBPL3).
Expression analysis:  To examine the expression of
C7orf9, RT-PCR analysis was performed with primers A129F3
and A129R amplifying a 244 bp transcript exclusively from
human retina but not from the other 19 tissues tested (Figure
3A). Northern blot hybridization confirmed this pattern of
expression (Figure 3B). Two bands of approximately 0.8 kb
and 1.2 kb were observed, suggesting that two of the three
hypothetical polyadenylation sites, those at 848 bp and 1156
bp, are used. In agreement with our findings, expression of
RFRP mRNA was shown in rat tissues to be restricted to hy-
pothalamus and eye [11].
Analysis of the C7orf9 gene as a candidate for CYMD:
The retinal expression of C7orf9 as well as the localization of
its genomic locus within the critical region for CYMD which
is limited by D7S493 distally and D7S2444 proximally ([5]
and unpublished data), makes this gene an excellent candi-
date for the CYMD gene. We therefore proceeded to analyze
C7orf9 in two affected individuals (numbers 10084 and 4716)
from the same large Dutch CYMD pedigree that was used to
establish linkage [5].
We sequenced the complete coding region of the gene in
both patients and an unrelated unaffected individual. The un-
affected individual is heterozygous for a 172A->G alteration
while patient number 10084 revealed heterozygosity for a
143G->C nucleotide substitution and individual number 4716
heterozygosity for a 431C->T alteration. The 143G->C and
the 172A->G changes result in non-conservative amino acid
substitutions from methionine at codon 32 to isoleucine and
from aspartate at codon 42 to glycine, respectively. In con-
trast, the 431C->T variant does not alter the amino acid se-
quence of the putative protein. We conclude that neither of the
nucleotide changes 143G->C and 431C->T is likely to be dis-
ease causing as both affected individuals belong to the same
extended pedigree and would be expected to carry the same
disease causing mutation. Moreover, in a group of unaffected
controls, we have determined the minor allele frequency for
143G->C, 172A->G and 431C->T to be 0.07, 0.27 and 0.27,
respectively, demonstrating their polymorphic nature (Table
1). Heterozygosity of both patients at the 143G->C and 431C-
>T sites confirms that both carry two C7orf9 alleles. This rules
out the possibility of a heterozygous deletion involving the
entire gene, a situation that would otherwise have remained
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Figure 4. Southern blot analysis of C7orf9 locus.  DNAs from pa-
tient number 4716 and an unrelated control were digested with re-
striction enzymes EcoRI, HincII, and PstI and probed with a cDNA
fragment representing the full-length transcript including the 5' and
3' UTRs. No gross intragenic rearrangements are observed.
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undetected by PCR amplification. Further investigation of the
C7orf9 gene locus in patient number 4716 by Southern blot
analysis using restriction enzymes EcoRI, HincII and PstI also
showed no evidence of gross intragenic rearrangements (Fig-
ure 4).
This work provides the characterization of the C7orf9 gene
and its evaluation as a candidate for CYMD. The lack of mu-
tations in the coding exons and lack of evidence for gross re-
arrangements argues against a causative role for C7orf9 mu-
tations in the etiology of CYMD. It should be noted, however,
that small mutations in the promoter sequences or within the
intronic regions are difficult to assess and have not been ex-
cluded in this study. The knowledge of the gene structure of
C7orf9 will facilitate further mutational analyses in other he-
reditary retinal dystrophies with as yet unknown genetic causes.
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